NDASUBCUTANEOUSINJECTABLEPriority Review
Approved
Mar 1993
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Clinical Trials
4
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Lovenox (enoxaparin sodium) is a low-molecular-weight heparin (LMWH) anticoagulant administered via subcutaneous injection. It is used to prevent and treat blood clots in conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and acute coronary syndromes. The preservative-free formulation reduces potential irritation and is preferred in sensitive patient populations.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (45/100), signaling potential downsizing of brand marketing and transition to lifecycle management focus.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Effectiveness & Safety of Ovine Enoxaparin Sodium to Originator Enoxaparin in Non-ST-Segment Elevation ACS Patients
Started Jun 2023
220 enrolled
Safety IssuesEffect of Drug
A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)
Started Jul 2008
0Small Cell Lung Cancer
Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)
Started Jun 2006
156 enrolled
Arthroplasty, Replacement, Hip
The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.
Started Aug 2005
35 enrolled
Deep Vein Thrombosis
Worked on LOVENOX (PRESERVATIVE FREE) at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.